Nazanin Razazian - Department of Neurology, Neuroscience Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Mohammad-Ali Sahraian - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Sharareh Eskandarieh - Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Nooshin Jafari - Department of Neurology, Neuroscience Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Mansour Rezaei - Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Negin Fakhri - Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

Background: Vaccination against COVID-۱۹ for people with multiple sclerosis (PWMS) has been recommended, but long-term follow-up needs further research. Objectives: To follow up PWMS ۳ months after vaccination with the Sinopharm vaccine regarding the relapse of MS and infection with COVID-۱۹. Materials & Methods: The participants in this prospective study were PWMS over ۱۸ years of age living in Kermanshah Province, Iran, who received two doses of the Sinopharm vaccine between August and November ۲۰۲۱. The information on demographic and clinical characteristics of PWMS, COVID-۱۹ infection, and relapses of MS ۳ months after vaccination, were collected. We contacted the patients using the information registered in the MS registry system of Kermanshah Province, and the study data were collected by phone call and using a researcher-made questionnaire. Results: Overall, ۱۹۷ MS patients with a Mean±SD age of ۴۱.۸۴±۱۱.۰ years, including ۱۵۵(۷۸.۷%) females and ۴۲(۲۱.۳%) males were studied. There was no significant difference (P=۱.۰۰۰) in MS relapse frequency between the time points of ۳ months before the first dose (۱۵[۷.۶%]) and ۳ months after the second dose (۱۵[۷.۶%]). The frequency of infection with COVID-۱۹ within ۳ months after the second dose (۲۶[۱۳.۲%]) was significantly (P=۰.۰۱۷) higher than that in the ۳ months before the first dose (۱۲[۶.۱%]). Within ۳ months after the second dose, most PWMS with MS relapse or COVID-۱۹ infection used oral and anti-CD۲۰ therapy. Conclusion: During the ۳ months after the second dose, the frequency of MS relapse was not different, but the frequency of COVID-۱۹ infection was higher.

COVID-۱۹, Sinopharm, Infections, Multiple sclerosis